Search
ARCoV
go.drugbank.com/drugs/DB15855ExperimentalManufactured as a liquid, ARCoV is thermostable at room temperature for at least 1 week. … As of July 2020, the vaccine candidate is set for Phase 1 clinical trials to investigate for safety, tolerance, and immunogenicity (ChiCTR2000034112).
Rilapladib
go.drugbank.com/drugs/DB05119InvestigationalRilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development. It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2...
Ramosetron
go.drugbank.com/drugs/DB09290InvestigationalIt is believed to have higher potency and longer antiemetic action than other 1st generation 5-HT3 antagonists such as ondansetron.
QR-333
go.drugbank.com/drugs/DB05533InvestigationalQR-333 has been investigated as a treatment for diabetic peripheral neuropathy.
Peginterferon alfacon-1
go.drugbank.com/drugs/DB05860ExperimentalPEGylation is a technology for the chemical attachment of polyethylene glycol (PEG) polymer chains to a broad range of drug substances such as peptides and proteins including antibody fragments; small
1alpha,24S-Dihydroxyvitamin D2
go.drugbank.com/drugs/DB06117ExperimentalStudies have shown LR-103 has the same potency as calcitriol, but much lower toxicity.
BW-A 58C
go.drugbank.com/drugs/DB06740ExperimentalBW-A 58C, also known as 2-(4-tert-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone, is an experimental naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy
Taspoglutide
go.drugbank.com/drugs/DB14027InvestigationalAs of May 2013 no new trials had been registered.
Lecithin, soybean
go.drugbank.com/drugs/DB14161Investigationalcomplex mixture of phospholipids; glycolipids; and triglycerides; with substantial amounts of phosphatidylcholines; phosphatidylethanolamines; and phosphatidylinositols, which are sometimes loosely termed as
CIGB 2020 Vaccine
go.drugbank.com/drugs/DB15808ExperimentalAs of July, 2020, a Randomized control clinical trial (RPCEC00000306) is underway to evaluate prophylaxis potential in suspected contacts of Covid-19 patients.